Search
Haemonetics Corp
HAEAdd to Watchlist
75.020USD
-0.100-0.13%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.41BMarket Cap
36.37P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.13%
5 Days
+3.08%
1 Month
+10.63%
6 Months
-6.40%
Year to Date
-6.40%
1 Year
+0.55%
Key Figures
74.580Open
75.780High
562.61KVolume
36.37P/E TTM
14.23P/E Dynamic
--Dividend TTM
1.24%Turnover Ratio
75.120Prev. Close
72.340Low
19.02MTurnover
20.25P/E Static
4.26P/B
0.00%Div Yield TTM
4.02%ROA
87.32052wk High
0.68Volume Ratio
167.68MNet Profit
45.25MShares
2.0625EPS TTM
0.55Beta
12.03%ROE
47.31552wk Low
4.58%Amplitude
54.22%Gross Margin
3.41BMarket Cap
4.26Reward/Risk
2.76%Risk Rate
TradingKey Stock Score of Haemonetics Corp
Currency: USD Updated: 2026-06-30Key Insights
Haemonetics Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.78.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haemonetics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Haemonetics Corp Highlights
StrengthsRisks
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Overvalued
The company’s latest PE is 36.36, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 58.91M shares, increasing 1.11% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 8.81K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.33.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
87.778
Target Price
+16.85%
Upside Space
Haemonetics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Haemonetics Corp Info
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Ticker SymbolHAE
CompanyHaemonetics Corp
CEOSimon (Christopher A)
Websitehttps://www.haemonetics.com
Related Instruments
-1.10%
-1.12%
-2.20%
-2.04%
-1.28%
-0.15%
-4.84%
-3.35%
-0.64%
-0.36%
-1.11%
-1.86%
+0.49%
-0.86%
-0.43%
+2.15%
-2.57%
-1.77%
-0.32%
-0.03%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of Haemonetics Corp (HAE)?
The current price of Haemonetics Corp (HAE) is 75.02.
What is the symbol of Haemonetics Corp?
The ticker symbol of Haemonetics Corp is HAE.
What is the 52-week high of Haemonetics Corp?
The 52-week high of Haemonetics Corp is 87.32.
What is the 52-week low of Haemonetics Corp?
The 52-week low of Haemonetics Corp is 47.31.
What is the market capitalization of Haemonetics Corp?
The market capitalization of Haemonetics Corp is 3.39B.
Is Haemonetics Corp (HAE) currently rated as Buy, Hold, or Sell?
According to analysts, Haemonetics Corp (HAE) has an overall rating of Buy, with a price target of 87.78.
What is the Earnings Per Share (EPS TTM) of Haemonetics Corp (HAE)?
The Earnings Per Share (EPS TTM) of Haemonetics Corp (HAE) is 2.06.